Standardization of an experimental murine model of invasive pulmonary aspergillosis.
Evaluating new therapeutic agents for invasive aspergillosis requires animal models that are reproducible among different laboratories. We therefore evaluated a murine model of aerosol infection in two independent laboratories and found a high level of both intra- and interlaboratory reproducibility of survival, fungal burden over time, and the efficacy of liposomal amphotericin B.
Sheppard
Donald C
DC
McGill University, Department of Microbiology and Immunology, Montreal, Quebec, Canada. donald.sheppard@mcgill.ca
Graybill
John R
JR
Najvar
Laura K
LK
Chiang
Lisa Y
LY
Doedt
Thomas
T
Kirkpatrick
William R
WR
Bocanegra
Rosie
R
Vallor
Ana C
AC
Patterson
Thomas F
TF
Filler
Scott G
SG
D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality; D001232:Aspergillus fumigatus / Q000302:isolation & purification / Q000472:pathogenicity*; D004195:Disease Models, Animal; D006801:Humans; D008081:Liposomes; D008168:Lung / Q000382:microbiology; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality; D051379:Mice; D015203:Reproducibility of Results; D016896:Treatment Outcome
D000935:Antifungal Agents; D008081:Liposomes; C068538:liposomal amphotericin B; D000666:Amphotericin B